Drospifem 30, 21 tablets — Made in Germany — Free Delivery

Drospifem 30 tablets are indicated for oral contraception.

Active ingredients: ethinylestradiol, drospirenone;

1 tablet contains 0.03 mg of ethinylestradiol and 3 mg of drospirenone;

Excipients: lactose, corn starch, maltodextrin, magnesium stearate, Opadry 10A32290 yellow (hypromellose, talc, titanium dioxide (E 171), polysorbate 80, iron oxide yellow (E 172).

The presence or risk of developing venous thromboembolism (VTE).

The presence or risk of developing arterial thromboembolism (ATE).

Current or history of severe liver disease until liver function tests have returned to normal.

Severe renal failure or acute renal failure.

The presence of liver tumors at present or in history (benign or malignant). Or suspected malignant tumors (for example, genital or mammary glands), dependent on sex hormones.

Vaginal bleeding of unknown etiology.

Simultaneous use with preparations containing ombitasvir / paritaprevir / ritonavir and dazabuvir.

Hypersensitivity to the active substances or to any of the components of the preparation.

The tablets should be taken daily at approximately the same time, with a small amount of liquid if necessary, in the order indicated on the blister pack. Take 1 tablet daily for 28 consecutive days, continuously. Reception of tablets from each next package should begin the next day after the end of the previous package. Menstrual-like bleeding usually occurs on the 2-3rd day after the start of the placebo tablets and does not necessarily end before the start of the tablets from the new package.

Application is contraindicated.

The preparation Drospifem 30 is indicated for use as prescribed by a doctor only after the onset of persistent menstruation.

Does not affect.

So far, there are no data on preparation overdose with Drospifem 30. General experience with COCs shows that overdose may cause nausea, vomiting and withdrawal bleeding. Withdrawal bleeding can occur in girls even before menarche in case of inadvertent/accidental preparation use. There is no specific antidote; treatment should be symptomatic.

Mental disorders: emotional lability.

From the nervous system: headache.

From the gastrointestinal tract: nausea.

From the reproductive system and mammary glands: soreness of the mammary glands, metrorrhagia, amenorrhea.

Information about the medicinal product used concomitantly should be reviewed to identify potential interactions.

Interactions are possible with preparations that induce microsomal enzymes. This can lead to increased clearance of sex hormones, which in turn can cause breakthrough bleeding and/or loss of contraceptive effectiveness.

In patients with renal insufficiency, the simultaneous use of drospirenone and ACE inhibitors or non-steroidal anti-inflammatory preparations does not significantly affect the level of potassium in the blood serum. However, the simultaneous use of the preparation Drospifem 30 and aldosterone antagonists or potassium-sparing diuretics has not been studied. In this case, it is necessary to study the level of potassium in the blood serum during the first cycle of taking the preparation.

Keep out of the reach of children in the original packaging at a temperature not exceeding 30°C.

Shelf life - 3 years.